Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World dupixent: does it live up to the hype for eczema?

NCT ID NCT03992417

Knowledge-focused Sponsor: Sanofi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This study follows about 955 people aged 12 and older who are starting treatment with Dupixent (dupilumab) for atopic dermatitis, commonly known as eczema. The goal is to see how the drug performs in everyday clinical practice, not just in controlled trials. Researchers will track patients' medical history, treatment patterns, and long-term effectiveness, as well as any side effects. The findings could help doctors better understand who benefits most from Dupixent and how to use it optimally.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dupilumab (Dupixent), an injectable biologic drug for atopic dermatitis
What this could lead to
If successful, this study could provide a clearer picture of how Dupixent performs in real-world settings, helping doctors tailor treatment for different patients.
What could go wrong
Because this is an observational study, it cannot prove cause and effect. Results may be influenced by factors like patient selection and adherence, and long-term safety data are still being collected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

955 people

The number who actually took part.

Started

Jun 2019

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The target population is adult and adolescent patients (male or female, ≥12 years old), who are initiating treatment with Dupixent® for AD according to the country-specific prescribing information.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female, 12 years or older at the baseline visit. Note: Adolescent participants (at least 12 years old, but less than 18 years) are eligible only after Dupixent® receives the respective country's regulatory approval for use in this age group; * Initiating treatment with Dupixent® for AD according to the country-specific prescribing information. Note: Participants may be eligible if they have already initiated treatment with Dupixent® for AD within 6 months before their enrollment in the registry, provided that all core baseline data required (Eczema Area and Severity Index \[EASI\], Scoring of Atopic Dermatitis \[SCORAD\], body surface area \[of AD involvement\] \[BSA\], Patient-Oriented Eczema Measure \[POEM\], and Dermatology Life Quality Index \[DLQI\]) by the registry protocol were captured at the time of initiating Dupixent® treatment and are available for entry in the registry database * Able to understand and complete study-related questionnaires * Provide signed informed consent or parental/legally acceptable representative consent and/or patient assent where applicable Exclusion Criteria: * Participants who have a contraindication to the drug according to the country-specific prescribing information label * Any condition that, in the opinion of the investigator, may interfere with patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other co-morbidities that can predictably prevent the participant patient from adequately completing the schedule of visits and assessments * Patients currently participating in any interventional clinical trial which modifies patient care * Prior use of Dupixent® within 6 months of the screening visit, or within 6 months of the baseline visit if screening and baseline occur on the same day The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dermatitis, atopic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dermatitis, atopic

Contacts and locations

Locations

  • Investigational Site Number : 0320011

    Ciudad Autonoma Bs As, C1121ABE, Argentina

  • Investigational Site Number : 0320012

    Rosario, Santa Fe Province, S2000DBS, Argentina

  • Investigational Site Number : 0320013

    Pilar, Buenos Aires, B1629ODT, Argentina

  • Investigational Site Number : 0360001

    Carlton, Victoria, 3053, Australia

  • Investigational Site Number : 0360002

    Kogarah, New South Wales, 2217, Australia

  • Investigational Site Number : 0360003

    Woolloongabba, Queensland, 4102, Australia

  • Investigational Site Number : 0360004

    Bedford Park, South Australia, 5042, Australia

  • Investigational Site Number : 0360005

    Kogarah, New South Wales, 2217, Australia

  • Investigational Site Number : 0400001

    Vienna, 1220, Austria

  • Investigational Site Number : 0400002

    Maria Enzersdorf, 2344, Austria

  • Investigational Site Number : 0400004

    Linz, 4020, Austria

  • Investigational Site Number : 0400005

    Graz, 8036, Austria

  • Investigational Site Number : 0560001

    Leige, 4000, Belgium

  • Investigational Site Number : 0560002

    Brussels, 1200, Belgium

  • Investigational Site Number : 0560003

    Jette, 1090, Belgium

  • Investigational Site Number : 0560006

    Roeselare, 8800, Belgium

  • Investigational Site Number : 0560007

    Edegem, 2650, Belgium

  • Investigational Site Number : 0560008

    Leuven, 3000, Belgium

  • Investigational Site Number : 0560010

    Ghent, 9000, Belgium

  • Investigational Site Number : 1580011

    Taichung, 40201, Taiwan

  • Investigational Site Number : 1580012

    Kaohsiung City, 833401, Taiwan

  • Investigational Site Number : 1580014

    Taipei, 100, Taiwan

  • Investigational Site Number : 1580015

    Taoyuan County, 333, Taiwan

  • Investigational Site Number : 1700008

    Bogotá, 11001, Colombia

  • Investigational Site Number : 1700011

    Medellín, 050034, Colombia

  • Investigational Site Number : 1700012

    Bogotá, 110221, Colombia

  • Investigational Site Number : 2030001

    Ústí nad Labem, 40113, Czechia

  • Investigational Site Number : 2030002

    Prague, 150 06, Czechia

  • Investigational Site Number : 2030003

    Ostrava - Poruba, 70852, Czechia

  • Investigational Site Number : 2030004

    Pilsen, 304 60, Czechia

  • Investigational Site Number : 2030005

    Prague, 110 01, Czechia

  • Investigational Site Number : 2030006

    Olomouc, 77900, Czechia

  • Investigational Site Number : 2030008

    Hradec Králové, 50005, Czechia

  • Investigational Site Number : 2460002

    Kokkola, 67200, Finland

  • Investigational Site Number : 2500001

    Valence, 26953, France

  • Investigational Site Number : 2500002

    Toulouse, 31059, France

  • Investigational Site Number : 2500003

    Bordeaux, 33000, France

  • Investigational Site Number : 2500005

    Saint-Mandé Cedex, 94160, France

  • Investigational Site Number : 2500006

    Pierre-Bénite, 69495, France

  • Investigational Site Number : 2500009

    Montpellier, 34295, France

  • Investigational Site Number : 2500010

    Rouen, 76000, France

  • Investigational Site Number : 2500011

    Antony, 92160, France

  • Investigational Site Number : 3000001

    Thessaloniki, 56403, Greece

  • Investigational Site Number : 3000003

    Thessaloniki, 54645, Greece

  • Investigational Site Number : 3760001

    Haifa, 3109601, Israel

  • Investigational Site Number : 3760002

    Jerusalem, 91120, Israel

  • Investigational Site Number : 3760004

    Ramat Gan, 5266202, Israel

  • Investigational Site Number : 3760005

    Haifa, 31048, Israel

  • Investigational Site Number : 3760006

    Afula, 18101, Israel

  • Investigational Site Number : 3800001

    Naples, 80131, Italy

  • Investigational Site Number : 3800003

    Rome, Roma, 00133, Italy

  • Investigational Site Number : 3800004

    Milan, 20122, Italy

  • Investigational Site Number : 3800005

    Roma, 00137, Italy

  • Investigational Site Number : 3800007

    Brescia, 25123, Italy

  • Investigational Site Number : 3800008

    Genova, 16132, Italy

  • Investigational Site Number : 3800009

    Torrette Di Ancona, Ancona, 60126, Italy

  • Investigational Site Number : 3800010

    Pisa, 56126, Italy

  • Investigational Site Number : 3800011

    Rome, Roma, 00161, Italy

  • Investigational Site Number : 3800012

    Bari, 70124, Italy

  • Investigational Site Number : 3800013

    Cagliari, 09124, Italy

  • Investigational Site Number : 3800015

    L’Aquila, 67100, Italy

  • Investigational Site Number : 3800016

    Torino, 10126, Italy

  • Investigational Site Number : 3800017

    Terracina, Latina, 04019, Italy

  • Investigational Site Number : 3920001

    Nagoya, 454-8509, Japan

  • Investigational Site Number : 3920002

    Habikino-shi, 583-8588, Japan

  • Investigational Site Number : 3920003

    Itabashi-ku, Tokyo, 173-8606, Japan

  • Investigational Site Number : 3920004

    Nagakute-shi, Aichi-ken, 480-1195, Japan

  • Investigational Site Number : 3920005

    Shimotsuga-gun, Tochigi, 321-0293, Japan

  • Investigational Site Number : 3920006

    Sapporo, Hokkaido, 060-0807, Japan

  • Investigational Site Number : 3920008

    Koshigaya-shi, Saitama, 343-8555, Japan

  • Investigational Site Number : 3920010

    Setagaya-ku, 156-0043, Japan

  • Investigational Site Number : 3920011

    Hirakata-shi, Osaka, 573-1191, Japan

  • Investigational Site Number : 3920012

    Minokamo-shi, 505-8503, Japan

  • Investigational Site Number : 3920013

    Marugame-shi, 763-0074, Japan

  • Investigational Site Number : 3920014

    Hamamatsu, 430-0929, Japan

  • Investigational Site Number : 3920015

    Obihiro-shi, Hokkaido, 080-0013, Japan

  • Investigational Site Number : 3920020

    Yokohama, 234-8503, Japan

  • Investigational Site Number : 3920022

    Amagasaki-shi, 660-8550, Japan

  • Investigational Site Number : 3920025

    Kyoto, 604-8845, Japan

  • Investigational Site Number : 4140001

    Sulaibikat, 90806, Kuwait

  • Investigational Site Number : 4840001

    Guadalajara, Jalisco, 44130, Mexico

  • Investigational Site Number : 5280002

    Bergen op Zoom, 4624 VT, Netherlands

  • Investigational Site Number : 5780001

    Bodø, 8005, Norway

  • Investigational Site Number : 5780002

    Bergen, N-5021, Norway

  • Investigational Site Number : 6200001

    Vila Nova de Gaia, 4434-502, Portugal

  • Investigational Site Number : 6200002

    Lisbon, 1169-050, Portugal

  • Investigational Site Number : 6200003

    Coimbra, 3000-075, Portugal

  • Investigational Site Number : 6200004

    Porto, 4099-001, Portugal

  • Investigational Site Number : 6430001

    Moscow, 123182, Russia

  • Investigational Site Number : 6430004

    Saint Petersburg, 191015, Russia

  • Investigational Site Number : 6820013

    Dammam, 31444, Saudi Arabia

  • Investigational Site Number : 7240001

    Madrid, 28041, Spain

  • Investigational Site Number : 7240002

    Oviedo, Principality of Asturias, 33011, Spain

  • Investigational Site Number : 7240004

    Las Palmas de Gran Canaria, Las Palmas, 35010, Spain

  • Investigational Site Number : 7240006

    Madrid, 28034, Spain

  • Investigational Site Number : 7240007

    Madrid, 28031, Spain

  • Investigational Site Number : 7240008

    Santiago de Compostela, 15706, Spain

  • Investigational Site Number : 7240009

    Barcelona, 08041, Spain

  • Investigational Site Number : 7240010

    Madrid, 28040, Spain

  • Investigational Site Number : 7240012

    Majadahonda, Madrid, 28222, Spain

  • Investigational Site Number : 7240014

    Barcelona, Spain

  • Investigational Site Number : 7240016

    Madrid, 28006, Spain

  • Investigational Site Number : 7240017

    Barakaldo, 48903, Spain

  • Investigational Site Number : 7240019

    Bilbao, Bizkaia, 48013, Spain

  • Investigational Site Number : 7840002

    Abu Dhabi, 34761, United Arab Emirates

More trials for these conditions

Other studies related to the condition(s) this trial covers.